No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Polaryx Therapeutics, Inc. Common Stock (PLYX) stock was $2.08 as of Oct 6, 2026, 1:50 PM EDT, up 0.48% from the previous close.
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions.
Biotechnology · Paramus, NJ
LATEST PRICE
$2.08
52-WEEK RANGE
$1.85 - $48.91
BETA
-8.91
% FROM 52W HIGH
-95.75%
MARKET CAP
$103.68M
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
9.48
P/S RATIO
TTM
N/A
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
0.00
REVENUE TTM
$0
GROSS MARGIN TTM
0.00%
NET PROFIT MARGIN TTM
0.00%
REVENUE GROWTH TTM
TTM vs prior TTM
N/A
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
N/A
3Y TOTAL RETURN
annualized (CAGR)
N/A
5Y TOTAL RETURN
annualized (CAGR)
N/A
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.03
vs Estimate
$-0.04
Revenue
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 4 analysts
Average Price Target
$7.50
+260.6% upside
Low
$6.00
Current
$2.08
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.05 | $-0.05 | $-0.05 | 3 |
| Quarter ending Dec 2026 | $-0.06 | $-0.06 | $-0.05 | 3 |
| Quarter ending Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Quarter ending Jun 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.20 | $-0.20 | $-0.20 | 3 |
| FY 2027 | $-0.30 | $-0.29 | $-0.27 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PLYX | $103.68M | $2.08 | +0.48% | N/A | N/A | N/A | N/A |
| 2OKUR | $103.06M | $2.54 | -3.23% | -2.94% | -47.19% | N/A | vs PLYX |
| 3ANIX | $104.79M | $3.08 | +4.41% | -9.74% | -8.26% | -4.65% | vs PLYX |
| 4JYNT | $102.21M | $7.17 | -0.21% | -20.73% | -40.34% | +11.23% | vs PLYX |
| 5DH | $105.20M | $1.00 | +1.08% | -70.99% | -52.54% | N/A | vs PLYX |
| 6BDTX | $105.72M | $1.84 | -4.90% | -49.96% | -24.47% | N/A | vs PLYX |
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
